Drug Trial Radar · NCT04270669
Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Jan 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
37
Actual
Start
Apr 15, 2020
Primary completion
Oct 29, 2021
Study completion Oct 29, 2021
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a non-randomized, open-label, multicenter, 48-week study to investigate the efficacy, safety and pharmacokinetics of RC28-E injection in the treatment of patients with wet age-related macular degeneration by multiple administration.
Conditions
- Wet Age-Related Macular Degeneration
Interventions
intravitreal injection of RC28-E 0.5mgBiological
The patient received one treatment of RC28-E 0.5mg in the test group
intravitreal injection of RC28-E 1.0mgBiological
The patient received one treatment of RC28-E 1.0mg in the test group
intravitreal injection of RC28-E2.0mgBiological
The patient received one treatment of RC28-E 2.0mg in the test group
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change of BCVA from baseline at 12 week;Time frame: Baseline, Week 12
- Mean change of BCVA from baseline at 48 week;Time frame: Baseline, Week 48
- Incidence and severity of AEsTime frame: Baseline up to Week 48
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.